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Abstract
Summary This review provides a critical analysis of currently
available approaches to increase bone mass, structure and
strength through drug therapy and of possible direct intra-
osseous interventions for the management of patients at im-
minent risk of hip fracture.
Purpose Osteoporotic hip fractures represent a particularly
high burden in morbidity-, mortality- and health care-related
costs. There are challenges and unmet needs in the early pre-
vention of hip fractures, opening the perspective of new de-
velopments for the management of osteoporotic patients at
imminent and/or at very high risk of hip fracture. Amongst
them, preventive surgical intervention needs to be considered.
Methods A European Society for Clinical and Economic
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal
Diseases (ESCEO)/International Osteoporosis Foundation
(IOF) working group reviewed the presently available inter-
vention modalities including preventive surgical options for
hip fragility. This paper represents a summary of the
discussions.
Results Prevention of hip fracture is currently based on regu-
lar physical activity; prevention of falls; correction of nutri-
tional deficiencies, including vitamin D repletion; and phar-
macological intervention. However, efficacy of these various
measures to reduce hip fractures is at most 50% and may need
months or years before becoming effective. To face the chal-
lenges of early prevention of hip fractures for osteoporotic
patients at imminent and/or at very high risk of hip fracture,
preventive surgical intervention needs further investigation.
Conclusion Preventive surgical intervention needs to be ap-
praised for osteoporotic patients at imminent and/or at very
high risk of hip fracture.
Keywords Fracture . Osteoporosis . Treatment . BMD .
Bone strength . Surgical treatment
Introduction
Osteoporosis is a silent, asymptomatic disease affecting mil-
lions of older people of all ethnicities. The disease is dispro-
portionately observed in women, and it is estimated that 200
million women worldwide have osteoporosis [1]. The preva-
lence of osteoporosis in Europe in 2010 was estimated at 27.6
million, of which 22 million were women [1, 2]. Osteoporosis
is associated to a high risk of low-energy fractures of the hip,
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spine, proximal humerus or forearm. This risk significantly
increases with age, and approximately 90% of the fractures
are sustained in patients aged 60 years and older [3].
In the year 2000, there were an estimated 8.9 million new
osteoporotic fractures worldwide, comprising 1.6 million hip
fractures, 1.7 million forearm fractures and 1.4 million verte-
bral fractures. For these fractures, the female-to-male ratio was
1.6 [4]. In the Western world, the lifetime risk of any fracture
in women over the age of 50 years is in the order of 40–51%
and for hip fracture is 18–23% [5, 6]. Hip fracture is the most
severe type of fracture in osteoporotic patients. Its incidence is
highly variable from country to country (<100 to >400 per
100,000 habitants), as well as is the age-related exponential
increase with age [7]. By 2050, the worldwide annual number
of hip fractures is expected to reach 4.5 to 6.3 million,
reflecting the continuous ageing of the population [8, 9].
Osteoporotic hip fractures represent a particularly high bur-
den in economic costs as compared to other fracture sites [2].
Hip fracture commonly leads to long-term physical disability,
reducing quality of life and impairing the capacity to live
independently and perform daily activities [10]. The cascade
of consequences associated with hip fractures also includes
depression (that may result in slowed recovery), health co-
morbidities and increased risk of death [11–16].
Following a hip fracture, all-cause mortality rates are
higher within the first 3 months (5.75-fold higher in women
and 7.95-fold higher in men compared to controls) [17]. In
observational studies across the USA and Europe, 8–36% of
patients died within the first year [18–21], and the 5-year
mortality risk in this population was evaluated at 64% [22].
The 1-year morbidity rates after a hip fracture are higher in
elderly patients suffering from depression, delirium or demen-
tia, highlighting the need for personalised care [23]. It is dif-
ficult to determine the proportion of deaths that are causally
related to the hip fracture rather than due to morbidity, but
indirect evidence from the pattern of mortality with time sug-
gests that approximately 30% of deaths are a direct result of
the fracture event [24].
The burden of osteoporosis as evaluated by disability-
adjusted life years (DALYs) in Europe and the Americas
accounts for 2 million DALYs annually, which is more
than those explained by hypertensive heart disease [2].
In the USA, in 2005, osteoporosis-related hip fractures
in men and women over the age of 50 cost nearly $12.2
billion [25]. The economic burden of incident and prior
fragility fractures in the European Union was estimated
at € 37 billion in 2010. Incident fractures represented
66% of this cost, long-term fracture care 29% and phar-
macological prevention 5%. These costs are expected to
increase by 25% in 2025 [2].
Several tools have been developed to detect patients at
increased risk of fracture. The FRAX assessment tool is wide-
ly used to evaluate the fracture risk in osteoporotic patients
[26]. This tool based on simple questions assessing bone min-
eral density (BMD)-independent risk factors provides 10-year
probability of experiencing major osteoporotic fractures or
specifically hip fracture. BMD at the femoral neck can option-
ally be entered to enhance fracture prediction.
Second hip fractures tend to occur early following an
initial hip fracture. Annual incidence for a second hip
fractures ranges from 2 to 10% with a mean interval
between first and second hip fracture of approximately
2 years [27–29]. In hip fracture patients, the cumulative
incidences for second hip fracture range between 2.4
and 5.1% within the first year, 5.1 and 8.1% within
the first 2 years, 8.0 and 8.2% at 5 years and 8.6%
within the first 8 years [28, 30–32]. A retrospective
study of 241 hip fractures also reported that 11% of
the patients had previously experienced a contralateral
hip fracture on average 5.6 years before [33]. This risk
of recurrent hip fracture persists for at least 10 years
amongst hip fracture survivors, with a reported risk of
8% of a second fracture within 10 years [34, 35].
In this context, the benefits of coordinator-based systems to
ensure appropriate management of patients following a frac-
ture are well established [36–38]. The International
Osteoporosis Foundation (IOF) has launched a global cam-
paign (‘Capture the fracture™ ’) to promote this approach
for the prevention of a second fracture [36]. This initiative
aims to set internationally endorsed standards for best practice
by facilitating the implementation of fracture liaison services
(FLSs) involving best practice frameworks, multidisciplinary
models and FLS questionnaires [36–38]. Despite the major
burden associated with osteoporosis and fragility fracture
and the antifracture efficacy of the available therapies, there
is a marked treatment gap in osteoporosis, i.e. a significant
proportion of patients at high fracture risk or those who have
sustained a fragility fracture are not being treated [1, 2]. In
Europe, the treatment gap for osteoporosis ranges from 63 to
80% according to country and gender [1]. Only moderate
usage of treatments like calcium and vitamin D (8–62%, me-
dian 18%) postfracture is seen. Bisphosphonate usage is lower
(0.5–38%) [39]. In patients who sustain a fragility fracture, it
was reported that fewer than 20% of individuals receive ther-
apies (about 5% in the case of a first hip fracture) [40]. More
recent data indicate that in Europe and the USA, less than 25
and 20%, respectively, of patients with a hip fracture receive
osteoporosis medication, with less than 15% receiving
bisphosphonates [41].
These considerations highlight the need for appropriate
management options, particularly in very high-risk osteopo-
rotic patients. This review provides a critical analysis of cur-
rently available approaches to increase bone mass, structure
and strength through drug therapy and of possible direct intra-
osseous interventions for the management of patients at im-
minent risk of hip fracture.
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Methods
Relevant articles and reviews were identified through
PubMed/MEDLINE by working group members. Other items
were selected from the reference lists of related articles and the
presentations during the working group meeting.
Pathogenesis of osteoporotic fracture
A bone fracture occurs when the externally applied load ex-
ceeds its intrinsic load-bearing capacity. Thus, the resulting
bone deformation initiates tissue damage, which results in a
major crack through the bone structure (Fig. 1). Recent data
from a prospective study where hip strength was estimated by
finite element analyses (FEAs) actually demonstrates that vir-
tually, all hip fractures occur in subjects whose hip strength is
below 3000 N [42]. Areal bone mineral density (aBMD), as
measured by dual-energy X-ray absorptiometry (DXA), is the
most commonly used surrogate of bone strength [42–45].
aBMD accounts for 60 to 80% of bone strength variance.
However, bone strength also depends on bone geometry, mi-
crostructure and material properties [46–48]. It is therefore
important to recognise that the annual percentage loss of hip
strength exceeds the percentage loss of areal bone mineral
density and this difference increases exponentially with age,
emphasizing the importance of structural changes as a deter-
minant of bone fragility [49].
With the menopause and then ageing, early trabecular thin-
ning and loss of connectivity occur, leading to a weakening of
predominantly cancellous bone parts such as the vertebrae and
ultradistal radius. At the latter site, for instance, a 20% loss of
trabecular number or thickness have been estimated to cause a
10% loss of strength [50]. However, even at the distal radius,
the thin cortical shell (typically less than 1 mm) carries more
than 50% of the load [51], so that a 20% loss of cortical bone
volume at that site would cause a 37% loss of strength [50].
Hence, cortical thickness is a major contributor to bone
strength; however, its importance varies according to the bone
site and the mechanism of the fracture [52, 53]. Although there
is evidence that part of the axial load carried by the cortical
shell in the human vertebra increases with age [54], the overall
stiffness contribution of the cortical shell is almost balanced
with that of the trabecular component alone [55]. Cortical
porosity increases with age and represents a major contribu-
tion of the decrease in bone material stiffness and toughness
[56]. Hence, with ageing, the cortical bone becomes substan-
tially thinner, and more porous, leading to loss of elasticity
and increased fracture risk in a region, which undergoes com-
pression during a fall [57, 58]. At the hip, cortical thinning
occurs asymmetrically with ageing, so that the percentage of
bone loss is greater in the thinner superior cortex than in the
thicker inferior portion [59].
There is a shifting opinion regarding the origin of a hip
fracture, particularly with respect to the initiation of failure
in trabecular vs. cortical bone, and the importance of the tra-
becular network to contribute to hip strength. In the proximal
femur, a study suggested that removing the trabecular core of
the hip reduces by only 7% the all-hip strength in compres-
sion, which suggests a major contribution of cortical bone
[52]. However, this study has been heavily criticised because
the fracture was produced in stance loading and not in a side-
way fall loading. In the latter case scenario, fracture mecha-
nisms as identified in cadaver bone appear to involve com-
pression failure on the supero-lateral side (a region with little
cortical bone) and tension failure on the medial side (rich in
cortical bone) [60]. But, trabecular bone has the ability to
absorb some excess energy. In weakened, osteoporotic bones,
increasing trabecular strength provides improved structural
redundancy, thereby increasing the threshold for fracture ini-
tiation [61]. Cortical bone appears only to be engaged in the
failure process when there is insufficient trabecular strength in
the trochanteric and subcapital femoral neck regions to with-
stand the fall loading [61]. Once the cortex gets involved,
tissue-level failure appears in both bone compartments, with
equal contribution.
Therefore, in designing new approaches to restore bone
strength of the hip, both compartments should be considered
for reinforcement.
Fig. 1 Pathogenesis and overview of themanagement of the osteoporotic
fracture
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Current management options
Non-pharmacological options
Preventive measures include lifestyle interventions, fall
prevention and possibly the use of hip protectors
(Fig. 2). Hip pads are an example of such an approach,
as they aim to reduce to the amount of mechanical
energy transmitted to the hip following a fall, with
the hope that this will reduce the likelihood of frac-
ture. The effectiveness of this intervention is contro-
versial and also limited by poor compliance and accep-
tance [63–65].
Non-pharmacological interventions include dietary
modification, stopping smoking, avoiding excessive al-
cohol intake, regular weight bearing, balance restoring
and muscle-strengthening exercises [26, 66, 67].
Increasing physical activity, in combination of a nutri-
tional intervention enriched in calcium, proteins and vi-
tamin D, has been associated with increases in BMD in
postmenopausal women and improvement of muscle
strength [67–71]. Whilst adopting these measures may
have beneficial effects on bone health, evidence that
they prevent fractures is lacking [72]. Guidelines also
stress the importance of taking measures to prevent
falls. However, although fall prevention programmes
have been shown to reduce the frequency of falls, the
majority of studies in elderly subjects have failed to
show fracture reduction [73, 74].
Pharmacological treatments
Current pharmaceutical therapies for osteoporosis have been
shown to increase femoral neck and/or total hip aBMD and,
for some treatments, to reduce hip fracture risk. Across all
placebo-controlled trials involving all sorts of osteoporosis
drugs, hip BMD gain explains near to 60% of hip fracture
reduction [75]. However, comparison between medications
is difficult because of largely different fracture risk in the
studied populations.
Alendronate, risedronate, zoledronic acid and denosumab
have all been shown to significantly decrease the risk of hip
fracture by approximately 40–50% in preplanned intention to
treat analyses [76–81]. This percentage reduction can be con-
sidered as a benchmark against which to compare new drug
efficacy or interventions.
Alendronate A meta-analysis of 6 randomised controlled tri-
als in 6804 women with T-scores ≤−2.5 treated with
alendronate demonstrated a 55% risk reduction in hip frac-
tures [81].
Risedronate The HIP study evaluated 9331 women into two
groups; one group had diagnosed osteoporosis, and the other
had osteopenia but were considered to be at high risk of hip
fracture, since being older than 80 years and presenting non-
skeletal risk factors including poor gait and propensity to falls.
The incidence of hip fracture amongst all women assigned to
receive risedronate was 2.8% compared to 3.9% amongst
placebo-treated women (corresponding to a 28% reduction).
In the women with osteoporosis, the incidence was 1.9% in
risedronate treated vs. 3.2% in placebo treated (40% reduc-
tion) [80]. However, the protective effects for hip fracture with
risedronate were not significant in women aged 80 years and
older, who were not selected on the base of BMD but purport-
edly on their risk of falling, as compared to younger patients
[80].
Zoledronic acid The Health Outcomes and Reduced
Incidence with Zoledronic Acid Once Yearly (HORIZON)
trial enrolled 7765 postmenopausal women with osteoporosis
and demonstrated a 41% reduction in hip fracture rates fol-
lowing 3 years of zoledronic acid treatment when compared to
placebo [76].
Furthermore, the risk of a second hip fracture was assessed;
the 30% reduction in the risk of a second hip fracture did not
reach the level of statistical significance [82].
The lack of evidence for hip fracture reduction in women
aged 75 years and older in the two HORIZON studies, as
evidenced by a pooled analysis, might raise the point that
recurrent falls are the most prominent mechanism for hip frac-
ture in this population [83]. Alternatively, that the level of hip
Fig. 2 The fracture prevention triangle [62]. Adapted fromCryer C, Patel
S. Falls, fragility and fractures. National service framework for older
people. The case for and strategies to implement a joint health
improvement and modernisation plan for falls and osteoporosis.
London: Alliance for Better Bone Health, 2001
37 Page 4 of 12 Arch Osteoporos (2016) 11: 37
bone fragility at that age cannot easily be reversed in just few
years of pharmacological therapy.
Denosumab The FREEDOM trial evaluated 7808 patients
who received subcutaneous injections of either denosumab
or placebo once every 6 months for 3 years. Denosumab treat-
ment resulted in a 40% reduction of the incidence of hip frac-
tures [78], and increased cortical thickness at the hip and fe-
mur [84], as well as improving determinants of structure using
FEA and strength [85]. Moreover, in a preplanned subgroup
analysis in high-risk patients, hip fracture risk reduction in
75+ years old reached 62%.
Teriparatide In a trial of 1637 postmenopausal women with
osteoporosis, 20 and 40 μg of teriparatide daily subcutaneous-
ly were shown to reduce the incidence of new non-vertebral
fragility fractures (NVFs) by 35 to 53% [86]. Hip fractures
were not reduced, but there were less than 1% of women with
a hip fracture in this 18-month trial. In a review, Eriksen et al.
[87] suggest potential benefits of teriparatide on hip fracture
risk.
In a study conducted on over 4000 patients (the Direct
Assessment of non-vertebral fractures in Community
Experience (DANCE) study), the incidence rate of NVF was
beyond 6 months of treatment [88].
In the European Forsteo Observational Study (EFOS),
there was a 47% decrease in the odds of fracture in the last
6-month period of the 18-month trial. The NVF rates were
significantly decreased between the first and the last 6-
month period of treatment [89].
Strontium ranelate The Treatment of Peripheral
Osteoporosis (TROPOS) study evaluated the effects of stron-
tium ranelate in 5091 postmenopausal women with osteopo-
rosis. The trial demonstrated a 36% risk reduction for hip
fracture in a post hoc analysis subgroup (>74 years of age
and osteoporosis) over 3 years [90].
Odanacatib (investigational drug) In a phase III long-term
trial conducted on more than 16,000 postmenopausal women
with prior vertebral fracture, odanacatib, an investigational
cathepsin K inhibitor, showed a 47% relative reduction in
hip fractures [91].
Abaloparatide (investigational drug) Abaloparatide is a 34
amino acid peptide with 71% homology with PTHrP (1–34)
and 41% homology with PTH (1–34) that has been developed
for subcutaneous delivery in the treatment of osteoporosis. A
phase III, randomised controlled trial, BACTIVE,^ in a cohort
of ambulatory postmenopausal female patients with osteopo-
rosis evaluated the effect of abaloparatide-SC (80 μg daily) on
fracture risk. The number of hip fractures was too small (n = 3)
to allow any analysis, but non-vertebral fractures were signif-
icantly reduced by 43% [92].
Number needed to treat
The number of patients needed to treat (NNT) over a period of
3 years to prevent one hip fracture varies between 48 for
strontium ranelate and 200 for denosumab. NNT amounts to
91 for alendronate, risedronate and zoledronic acid [93]. The
NNT does not allow one to make any comparison between the
various agents since it is mainly determined by the absolute
risk, i.e. osteoporosis severity and clinical risk factors, in the
placebo group. Nevertheless it indicates how many women at
high risk of hip fractures—as included in those trials—would
need to be exposed to some sort of invasive procedure (see
below) to eventually prevent a hip fracture, in the event that a
local form of therapy was to be developed.
Current challenges
Poor adherence
Current treatments reduce hip fracture risk by up to 50% [94].
In the ‘real-world’ setting, this residual risk is amplified by
poor adherence [95].
Whilst some regimens are convenient, particularly the in-
jectable 6-month and 1-year forms, patient compliance to os-
teoporosis medications is poor and often below 50% after
1 year. Up to 60% of patients who take a once-weekly bis-
phosphonate and nearly 80% of those who take a once-daily
bisphosphonate discontinue treatment within a year [96].
Lack of adherence may arise from side effects from the
medications (e.g. gastrointestinal irritation) or fear of rare ad-
verse events (e.g. atypical femoral fractures, osteonecrosis of
the jaw) [97–99]. It could lead to a marked decrease in
antifracture efficacy of the prescribed treatments. Under-
prescription of efficacious drugs by caregivers despite mark-
edly elevated fracture risk should also be mentioned.
Onset of fracture risk reduction
Several studies have suggested that there is a lag time between
the onset of treatment with bisphosphonates and fracture risk
reduction. For example, for zoledronic acid, after the first hip
fracture, the 30% reduction in the second hip fracture was
evident after 16 months of treatment [76, 78, 100, 101]. For
denosumab, the incidence curves appeared to diverge by
about 9 months [78]. The study of the onset of effect is prob-
lematic due to the low number of outcome events but, if true,
has implications for patient care. Furthermore, the onset of
action of different medications in different study populations
can barely be compared, since a higher risk of fracture in the
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population under study is associated with an earlier achieve-
ment of statistical significance.
These considerations may indicate a need for early effica-
cious therapeutic options for those patients at imminent and
very high risk of hip fracture. This would be particularly rel-
evant following a first hip fracture. Indeed, the relative risk of
re-fracture increases rapidly following a fracture and is max-
imal in the first year. To address these unmet needs, a specific
subtype of patients that would benefit from additional ap-
proaches, including surgical preventive bone enhancement,
may need to be identified (Fig. 3). Nevertheless, the risk of
second fracture persists 10 years after the first one; therefore,
secondary prevention should continue beyond an early post-
fracture period [22, 27, 29].
Possible role of orthopaedic interventions
to strengthen bone
In addition to systemic treatments, procedures developed for
fracture immobilisation or for filling up local bone defect (e.g.
bone tumours/cysts, hemangioma, avascular necrosis) have
been proposed to strengthen fragile bone, particularly proxi-
mal femur, prior to fracture occurrence [102]. Techniques are
prophylactic nailing, femoroplasty with cement and bone
grafting with osteoconductive or osteoinductive materials
(Table 1) [103]. Like for most of the systemic therapies, these
approaches do not correct the microstructural alterations.
Further studies are required to identify indications and to get
registration.
The main target for preventive orthopaedic surgery is the
frail oldest old, at markedly elevated risk of fracture, who is
the most likely to benefit from fracture prevention. This type
of patients is also the most susceptible to present co-
morbidities and to develop presurgery and postsurgery medi-
cal complications. In addition, anaesthesia’s risks should also
be integrated into a risk/benefit assessment with quality of
remaining life years as the outcome.
Prophylactic nailing
To stabilise incomplete femoral atypical fractures, prophylac-
tic nailing has been recommended [104]. Such a prophylactic
nailing for highly fragile osteoporotic hips is not currently
performed in clinical practice [104]. In a randomised con-
trolled trial, contralateral hip fixation using a hydroxy-
apatite-coated titanium tubular screw was evaluated on the
risk of recurrent fracture [105]. Although the feasibility and
safety of the procedure were confirmed, the results were not
conclusive since no contralateral hip fracture occurred over
the 16-month follow-up. There is a device called Y-
STRUT®, which is indicated for contralateral percutaneous
internal fixation of proximal femur in patients with a low-
energy pertrochanteric fracture. This device is implanted dur-
ing the same anaesthesia [106]. The implant consists of two
interlocking peek rods linked with surgical cement
(polymethylmethacrylate (PMMA)). The loadings until fail-
ure of cadaver specimens with this implant showed increased
both fracture load (+18%) and energy to fracture (+32%) as
compared to contralateral femur. However, periprosthetic frac-
ture risk should be taken into consideration in a careful
benefit-risk and cost-effectiveness analysis for any new local
procedure aimed at preventing hip fractures [107]. Indeed,
prophylactic fixation with a cephalomedullary nail was not
found to be cost-effective in elderly women with hip fracture
[108]. However, the case may differ in selected patients.
Bone grafting
Bone graft materials are useful in situations where a large
volume defect needs to be refilled and also when the regener-
ative process is compromised (avascular necrosis, atrophic
non-union). Autologous bone grafts from the iliac crest will
not be reviewed here, as the duration of healing, the potential
risks and complications associated with this technique are not
compatible with the target population of elderly frail osteopo-
rotic patients that require a rapid increase in bone strength
[109–111].
Femoroplasty (cement augmentation)
Femoroplasty is a procedure in which cement, usually
PMMA, is injected into an osteoporotic proximal femur.
This technique has been only evaluated to date in ca-
daver or animals. The results showed 30–80% improve-
ment in bone strength, the results being volume depen-
dent (cement augmentations of 20 to 40 ml) and loca-
tion dependent [112–114].
The major drawback of this procedure is the exothermic
material properties of PMMA (temperature increases from
+18 to +30 °C) that can cause osteonecrosis when a large
volume of cement is injected [114].
As a consequence, Beckman et al. developed a procedure
where an 8-mm perforation is drilled in cadaver femurs and 8
to 18ml of cement is injected.With this approach, the increase
in fracture load (peak load to failure) was of lower magnitude
(+23–35%) [115]. In vitro verification of femoroplasty with
CT imaging to improve the procedure in terms of cement
distribution and location indicated an increase in the yield load
of +33% vs. control osteoporotic femora, for a cement volume
of 9.5 ± 1.7 ml [116]. This 33% improvement in yield load,
thereby reaching a value of 3000 N, by cement injection could
be considered as a benchmark for the development of future
interventions.
A study compared femoral augmentation using steel spirals
or cement-based femoroplasty [117]. Both metal implant and
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cement augmentation improved hip mechanical properties
when the load was applied on the greater trochanter. Both
procedures are simple, reproducible and minimally invasive.
Some studies on femoroplasty failed however to detect chang-
es in biomechanical properties. Comparing cement-based
femoroplasty to a minimally invasive fixation using the blade
of a proximal femur nail (PFNA™ Depuy Synthès), the au-
thors concluded that limited V-shaped PMMA augmentation
and PFNA blade insertion did not show any improvement in
failure load nor energy to failure [118]. In contrast to Beckman
et al. [115], another study concluded that 15 ml of cement was
not sufficient to augment the proximal femur and to provide
biomechanical advantage [119].
It is possible that femoroplasty may be associated with the
occurrence of subtrochanteric fractures, fat embolism, circu-
latory damage and stress concentration [114, 115, 119]. The
impact of femoroplasty on femur vascularisation is still un-
known. Thus, clinical validation of the technique is a research
priority.
Bone grafts with osteoconductive or osteoinductive
materials
Some bone graft substitutes, such as calcium phosphate bone
cements, resorbable polymers or allograft, can also serve as an
intra-osseous scaffold for delivery of bone anabolic agents
Table 1 Materials and properties
of bone graft substitutes used in
orthopaedics
Properties Materials
Cement Synthetic bone grafts Autograft
PMMA Osteoconductive Osteoinductive Autogenous
Osteoconductive (provides a scaffold for the
bone to grow inside)
× √ √ or ×a √
Osteoinductive (initiates bone formation) × × √ √
Osteogenic (comprises cells in the scaffold so
bone formation can start from within the
graft)
× × × √
Source: [103]
a Depends on carrier
Fig. 3 Levels of fracture risk in
osteoporosis and their
management
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capable of stimulating bone formation and augmenting bone
mass [120]. Synthetic bone grafts are mainly made of
calcium-phosphate (e.g. hydroxyapatite and tricalcium phos-
phate), bioglass and calcium sulphate [121]. Such materials
can be used as carriers for growth factors to enhance bone
graft efficacy, drugs (bisphosphonates) or ions (strontium) to
promote osteoblast proliferation [122–126]. Local administra-
tion of bone morphogenetic protein (rhBMP-2, rh-BMP-7) is
another example of osteoanabolic substances use. However,
the implant procedure may be accompanied by an intense first
phase of bone resorption when a high dose of BMPs is used,
which may preclude its use in osteoporosis [127, 128].
Presently, the bone graft administration field is very wide
(with orthopaedics, traumatology, maxilla-facial/dental ap-
plications), with the spine being its largest application site
(45% of procedures). The main drawback of bone graft sub-
stitutes is that they are usually used to fill a defect (e.g. left by
the extraction of a tumour or a cyst). In osteoporosis, the
administration of osteoconductive or osteoinductive mate-
rials requires fluid material to avoid injection under high
pressure in the trabecular bone network of the proximal
femur.
Conclusions
The prevention of hip fractures, the most devastating compli-
cation of osteoporosis, remains a challenge, considering that
only a minority of high-risk patients, including patients with a
recent hip fracture who carry at least a 10% early risk of
contralateral fracture, are actually given osteoporosis therapy;
that the efficacy of the most potent osteoporosis drugs to pre-
vent hip fractures is at best 50% after more than 12–18months
of therapy; and that 50% or more of the patients may have
discontinued osteoporosis therapy by then. Hence, comple-
mentary approaches to immediately prevent hip fractures in
patients at very high risk may need to be developed, including
surgical approaches.
Some new materials are currently being developed that are
synthetic, resorbable, osteoconductive and osteoinductive ma-
terials, with the aim of locally strengthening weak bone struc-
ture, e.g. hip, to fill a gap in the management of elderly pa-
tients with an increased imminent risk of hip fracture.
However, the acceptability of a minimal but still invasive pro-
cedure in frail patients added to the need to use clear surrogate
markers for bone strength improvement, together with the
identification of high risk most likely to benefit from the pro-
cedure, highlights the difficulty of clinical studies aimed at
demonstrating the benefits and safety profile of such innova-
tive devices. Intervention thresholds remain to be established
in a more global context of an encompassing risk-benefit anal-
ysis. Overall, the benefits should be in line with the risks.
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